BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, Ginis J, Severs J, Jansen KU, Gruber WC, Watson W. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis 2021;73:e1489-97. [PMID: 32716500 DOI: 10.1093/cid/ciaa1045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Narsingam S, Munson J, Drescher F. Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.07.035] [Reference Citation Analysis]
2 Lane JR, Tata M, Briles DE, Orihuela CJ. A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniae. Front Cell Infect Microbiol 2022;12:826264. [DOI: 10.3389/fcimb.2022.826264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sealy RE, Dayton B, Finkelstein D, Hurwitz JL. Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design. Viruses 2021;13:884. [PMID: 34064894 DOI: 10.3390/v13050884] [Reference Citation Analysis]
4 Joean O, Welte T. Vaccination and modern management of chronic obstructive pulmonary disease - a narrative review. Expert Rev Respir Med 2022;:1-10. [PMID: 35713962 DOI: 10.1080/17476348.2022.2092099] [Reference Citation Analysis]
5 Tamura K, Chang B, Shimbashi R, Watanabe H, Tanabe Y, Kuronuma K, Oshima K, Maruyama T, Fujita J, Abe S, Kasahara K, Nishi J, Kubota T, Kinjo Y, Fujikura H, Fukusumi M, Shimada T, Sunagawa T, Suzuki M, Yamamoto Y, Oishi K; Adult IPD Study Group. Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019. Vaccine 2022:S0264-410X(22)00502-3. [PMID: 35489986 DOI: 10.1016/j.vaccine.2022.04.062] [Reference Citation Analysis]
6 Golden AR, Fear T, Baxter M, Adam HJ, Martin I, Demczuk W, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018. Diagn Microbiol Infect Dis 2021;101:115447. [PMID: 34192638 DOI: 10.1016/j.diagmicrobio.2021.115447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Silva-Costa C, Gomes-Silva J, Teodoro I, Ramirez M, Melo-Cristino J, On Behalf Of The Portuguese Group For The Study Of Streptococcal Infections. Invasive Pneumococcal Disease in Adults in Portugal: The Importance of Serotypes 8 and 3 (2015-2018). Microorganisms 2021;9:1016. [PMID: 34066862 DOI: 10.3390/microorganisms9051016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Metcalf BJ, Chochua S, Walker H, Tran T, Li Z, Varghese J, Snippes Vagnone PM, Lynfield R, McGee L, Li Y, Pilishvili T, Beall B. Invasive Pneumococcal Strain Distributions and Isolate Clusters Associated With Persons Experiencing Homelessness During 2018. Clin Infect Dis 2021;72:e948-56. [PMID: 33150366 DOI: 10.1093/cid/ciaa1680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Min JY, Mwakingwe-Omari A, Riley M, Molo LY, Soni J, Girard G, Danier J. The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥50 Years: a Randomized Trial. J Infect 2021:S0163-4453(21)00651-4. [PMID: 34963639 DOI: 10.1016/j.jinf.2021.12.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rivera-Izquierdo M, Soler-Iborte E, de Rojas JP, Pegalajar-García MD, Gil-Villalba A, Ruiz-Villaverde R, Valero-Ubierna MDC. Factors Associated with Adverse Reactions to BNT162b2 COVID-19 Vaccine in a Cohort of 3969 Hospital Workers. Vaccines (Basel) 2021;10:15. [PMID: 35062676 DOI: 10.3390/vaccines10010015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lister AJJ, Le CF, Cheah ESG, Desa MNM, Cleary DW, Clarke SC. Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis. Pneumonia (Nathan) 2021;13:9. [PMID: 34030731 DOI: 10.1186/s41479-021-00086-7] [Reference Citation Analysis]
12 Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 2021:S0264-410X(21)01097-5. [PMID: 34507861 DOI: 10.1016/j.vaccine.2021.08.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
13 Cools F, Delputte P, Cos P. The search for novel treatment strategies for Streptococcus pneumoniae infections. FEMS Microbiol Rev 2021:fuaa072. [PMID: 33399826 DOI: 10.1093/femsre/fuaa072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Basset A, Wall E, Mitsi E, Deshusses C, Daly R, Pojar S, Reiné J, Guerra-Assuncao JA, Denis B, Jochems SP, Heyderman R, Brown J, Lu YJ, Ferreira DM, Malley R. Targeted Transcriptomic Screen of Pneumococcal Genes Expressed during Murine and Human Infection. Infect Immun 2022;90:e0017522. [PMID: 35674445 DOI: 10.1128/iai.00175-22] [Reference Citation Analysis]
15 McGuinness D, Kaufhold RM, McHugh PM, Winters MA, Smith WJ, Giovarelli C, He J, Zhang Y, Musey L, Skinner JM. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine 2021;39:4231-7. [PMID: 34074546 DOI: 10.1016/j.vaccine.2021.04.067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shirley M. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs. [DOI: 10.1007/s40265-022-01733-z] [Reference Citation Analysis]
17 Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study. Lancet Reg Health Eur 2021;7:100126. [PMID: 34557837 DOI: 10.1016/j.lanepe.2021.100126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Khatuntseva EA, Nifantiev NE. Cross reacting material (CRM197) as a carrier protein for carbohydrate conjugate vaccines targeted at bacterial and fungal pathogens. Int J Biol Macromol 2022;218:775-98. [PMID: 35872318 DOI: 10.1016/j.ijbiomac.2022.07.137] [Reference Citation Analysis]
19 Theilacker C, Fletcher MA, Jodar L, Gessner BD. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Microorganisms 2022;10:127. [PMID: 35056576 DOI: 10.3390/microorganisms10010127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
20 Stefanetti G, Borriello F, Richichi B, Zanoni I, Lay L. Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases. Front Cell Infect Microbiol 2022;11:808005. [DOI: 10.3389/fcimb.2021.808005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, Poehling KA, Pilishvili T. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:109-17. [PMID: 35085226 DOI: 10.15585/mmwr.mm7104a1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
22 Golden AR, Adam HJ, Baxter M, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018. Vaccine 2021;39:5474-83. [PMID: 34454785 DOI: 10.1016/j.vaccine.2021.08.061] [Reference Citation Analysis]
23 Abouqal R, Beji M, Chakroun M, Marhoum El Filali K, Rammaoui J, Zaghden H. Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco. Front Public Health 2022;10:903376. [DOI: 10.3389/fpubh.2022.903376] [Reference Citation Analysis]
24 Garcia Garrido HM, Haggenburg S, Schoordijk MCE, Meijer E, Tanck MWT, Hazenberg MD, Rutten CE, de Bree GJ, Nur E, Meek B, Grobusch MP, Goorhuis A. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2022;97:592-602. [PMID: 35147238 DOI: 10.1002/ajh.26493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Downs SL, Madhi SA, Van der Merwe L, Nunes MC, Olwagen CP. High-throughput nanofluidic real-time PCR to discriminate Pneumococcal Conjugate Vaccine (PCV)-associated serogroups 6, 18, and 22 to serotypes using modified oligonucleotides. Sci Rep 2021;11:23728. [PMID: 34887480 DOI: 10.1038/s41598-021-03127-9] [Reference Citation Analysis]
26 Oliveira GS, Oliveira MLS, Miyaji EN, Rodrigues TC. Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines (Basel) 2021;9:1338. [PMID: 34835269 DOI: 10.3390/vaccines9111338] [Reference Citation Analysis]
27 Asai N, Mikamo H. Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults. Microorganisms 2021;9:2342. [PMID: 34835468 DOI: 10.3390/microorganisms9112342] [Reference Citation Analysis]
28 Chang B, Tamura K, Fujikura H, Watanabe H, Tanabe Y, Kuronuma K, Fujita J, Oshima K, Maruyama T, Abe S, Kasahara K, Nishi J, Kubota T, Kinjo Y, Serizawa Y, Shimbashi R, Fukusumi M, Shimada T, Sunagawa T, Suzuki M, Oishi K; Adult IPD Study Group. Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan. Sci Rep 2022;12:3066. [PMID: 35197497 DOI: 10.1038/s41598-022-06950-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ricketson LJ, Lidder R, Thorington R, Martin I, Vanderkooi OG, Sadarangani M, Kellner JD. PCR and Culture Analysis of Streptococcus pneumoniae Nasopharyngeal Carriage in Healthy Children. Microorganisms 2021;9:2116. [PMID: 34683437 DOI: 10.3390/microorganisms9102116] [Reference Citation Analysis]
30 Klein NP, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully IL, Scott DA, Jansen KU, Gruber WC, Watson W. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine 2021;39:5428-35. [PMID: 34315611 DOI: 10.1016/j.vaccine.2021.07.004] [Reference Citation Analysis]
31 Silva-Costa C, Gomes-Silva J, Prados L, Ramirez M, Melo-Cristino J, On Behalf Of The Portuguese Group For The Study Of Streptococcal Infections, The Portuguese Study Group Of Invasive Pneumococcal Disease Of The Pediatric Infectious Disease Society. Pediatric Invasive Pneumococcal Disease Three Years after PCV13 Introduction in the National Immunization Plan-The Continued Importance of Serotype 3. Microorganisms 2021;9:1428. [PMID: 34361864 DOI: 10.3390/microorganisms9071428] [Reference Citation Analysis]
32 Tobuse AJ, Ang CW, Yeong KY. Modern vaccine development via reverse vaccinology to combat antimicrobial resistance. Life Sciences 2022;302:120660. [DOI: 10.1016/j.lfs.2022.120660] [Reference Citation Analysis]
33 Amicizia D, Astengo M, Paganino C, Piazza MF, Sticchi C, Orsi A, Varlese F, Hu T, Petigara T, Senese F, Prandi GM, Icardi G, Ansaldi F. Economic burden of pneumococcal disease in children in Liguria, Italy. Hum Vaccin Immunother 2022;:2082205. [PMID: 35695748 DOI: 10.1080/21645515.2022.2082205] [Reference Citation Analysis]
34 Kurihara E, Takeshita K, Tanaka S, Takeuchi N, Ohkusu M, Hishiki H, Ishiwada N. Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan. Microbiol Spectr 2022;:e0182221. [PMID: 35357224 DOI: 10.1128/spectrum.01822-21] [Reference Citation Analysis]
35 Weinberger B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 2021;18:38. [PMID: 34627326 DOI: 10.1186/s12979-021-00249-6] [Reference Citation Analysis]
36 Wyplosz B, Fernandes J, Sultan A, Roche N, Roubille F, Loubet P, Fougère B, Moulin B, Duhot D, Vainchtock A, Raguideau F, Lortet-Tieulent J, Blanc E, Moïsi J, Goussiaume G. Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study. Vaccine 2022:S0264-410X(22)00841-6. [PMID: 35811205 DOI: 10.1016/j.vaccine.2022.06.071] [Reference Citation Analysis]
37 Müller A, Kleynhans J, de Gouveia L, Meiring S, Cohen C, Hathaway LJ, von Gottberg A; for GERMS-SA. Streptococcus pneumoniae Serotypes Associated with Death, South Africa, 2012-2018. Emerg Infect Dis 2022;28:166-79. [PMID: 34932448 DOI: 10.3201/eid2801.210956] [Reference Citation Analysis]
38 Barbieri E, Porcu G, Hu T, Petigara T, Senese F, Prandi GM, Scamarcia A, Cantarutti L, Cantarutti A, Giaquinto C. A Retrospective Database Analysis to Estimate the Burden of Acute Otitis Media in Children Aged <15 Years in the Veneto Region (Italy). Children (Basel) 2022;9:436. [PMID: 35327808 DOI: 10.3390/children9030436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Essink B, Peterson J, Yacisin K, Lal H, Mirza S, Xu X, Scully IL, Scott DA, Gruber WC, Jansen KU, Watson W. A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age. Hum Vaccin Immunother 2021;17:2691-9. [PMID: 33661716 DOI: 10.1080/21645515.2021.1890511] [Reference Citation Analysis]
40 Subramanian R, Liyanapathirana V, Barua N, Sun R, Wang MH, Ng R, Nelson EAS, Hui DS, Ip M. Persistence of Pneumococcal Serotype 3 in Adult Pneumococcal Disease in Hong Kong. Vaccines (Basel) 2021;9:756. [PMID: 34358172 DOI: 10.3390/vaccines9070756] [Reference Citation Analysis]
41 Redin A, Ciruela P, de Sevilla MF, Gomez-Bertomeu F, Gonzalez-Peris S, Benitez MA, Trujillo G, Diaz A, Jou E, Izquierdo C, Perez-Moreno MO, Moraga-Llop F, Olsina M, Vinado B, Sanfeliu E, Garcia A, Gonzalez-di Lauro S, Garcia-Garcia JJ, Dominguez A, Sa-Leao R, Muñoz-Almagro C; Catalan Study Group of Invasive Pneumococcal Disease. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13. Microbiol Spectr 2021;9:e0115021. [PMID: 34878302 DOI: 10.1128/Spectrum.01150-21] [Reference Citation Analysis]
42 Bergman K, Härnqvist T, Backhaus E, Trollfors B, Dahl MS, Kolberg H, Ockborn G, Andersson R, Karlsson J, Mellgren Å, Skovbjerg S. Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden. BMC Infect Dis 2021;21:756. [PMID: 34348674 DOI: 10.1186/s12879-021-06430-y] [Reference Citation Analysis]
43 Hanada S, Takata M, Morozumi M, Iwata S, Fujishima S, Ubukata K; Invasive Pneumococcal Diseases Surveillance Study Group. Multiple comorbidities increase the risk of death from invasive pneumococcal disease under the age of 65 years. J Infect Chemother 2021;27:1311-8. [PMID: 33962862 DOI: 10.1016/j.jiac.2021.04.018] [Reference Citation Analysis]
44 Buchwald UK, Andrews CP, Ervin J, Peterson JT, Tamms GM, Krupa D, Ajiboye P, Roalfe L, Krick AL, Sterling TM, Wang M, Martin JC, Stek JE, Kohn MA, Folaranmi T, Abeygunawardana C, Hartzel J, Musey LK; V110–029 Study Group. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Hum Vaccin Immunother 2021;:1-13. [PMID: 34019468 DOI: 10.1080/21645515.2021.1888621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Fitz-Patrick D, Young M Jr, Scott DA, Scully IL, Baugher G, Peng Y, Jansen KU, Gruber W, Watson W. A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Hum Vaccin Immunother 2021;17:2249-56. [PMID: 33545022 DOI: 10.1080/21645515.2020.1863177] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]